Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
2005 1
2007 1
2008 1
2009 2
2012 3
2013 1
2014 1
2015 1
2016 3
2017 1
2018 3
2019 3
2020 10
2021 1
2022 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Chaperome heterogeneity and its implications for cancer study and treatment.
Wang T, Rodina A, Dunphy MP, Corben A, Modi S, Guzman ML, Gewirth DT, Chiosis G. Wang T, et al. Among authors: dunphy mp. J Biol Chem. 2019 Feb 8;294(6):2162-2179. doi: 10.1074/jbc.REV118.002811. Epub 2018 Nov 8. J Biol Chem. 2019. PMID: 30409908 Free PMC article. Review.
First-in-human imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate.
Tendler S, Dunphy MP, Agee M, O'Donoghue J, Aly RG, Choudhury NJ, Kesner A, Kirov A, Mauguen A, Baine MK, Schoder H, Weber WA, Rekhtman N, Lyashchenko SK, Bodei L, Morris MJ, Lewis JS, Rudin CM, Poirier JT. Tendler S, et al. Among authors: dunphy mp. medRxiv [Preprint]. 2024 Jan 11:2024.01.10.24301109. doi: 10.1101/2024.01.10.24301109. medRxiv. 2024. Update in: Lancet Oncol. 2024 Aug;25(8):1015-1024. doi: 10.1016/S1470-2045(24)00249-3. PMID: 38260492 Free PMC article. Updated. Preprint.
Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.
Tendler S, Dunphy MP, Agee M, O'Donoghue J, Aly RG, Choudhury NJ, Kesner A, Kirov A, Mauguen A, Baine MK, Schoder H, Weber WA, Rekhtman N, Lyashchenko SK, Bodei L, Morris MJ, Lewis JS, Rudin CM, Poirier JT. Tendler S, et al. Among authors: dunphy mp. Lancet Oncol. 2024 Aug;25(8):1015-1024. doi: 10.1016/S1470-2045(24)00249-3. Epub 2024 Jun 28. Lancet Oncol. 2024. PMID: 38950555 Clinical Trial.
Optimizing 90Y Particle Density Improves Outcomes After Radioembolization.
Maxwell AWP, Mendoza HG, Sellitti MJ, Camacho JC, Deipolyi AR, Ziv E, Sofocleous CT, Yarmohammadi H, Maybody M, Humm JL, Schwartz J, Juluru K, Dunphy MP, Boas FE. Maxwell AWP, et al. Among authors: dunphy mp. Cardiovasc Intervent Radiol. 2022 Jul;45(7):958-969. doi: 10.1007/s00270-022-03139-6. Epub 2022 Apr 22. Cardiovasc Intervent Radiol. 2022. PMID: 35459960 Free PMC article.
Paradigms for Precision Medicine in Epichaperome Cancer Therapy.
Pillarsetty N, Jhaveri K, Taldone T, Caldas-Lopes E, Punzalan B, Joshi S, Bolaender A, Uddin MM, Rodina A, Yan P, Ku A, Ku T, Shah SK, Lyashchenko S, Burnazi E, Wang T, Lecomte N, Janjigian Y, Younes A, Batlevi CW, Guzman ML, Roboz GJ, Koziorowski J, Zanzonico P, Alpaugh ML, Corben A, Modi S, Norton L, Larson SM, Lewis JS, Chiosis G, Gerecitano JF, Dunphy MPS. Pillarsetty N, et al. Among authors: dunphy mps. Cancer Cell. 2019 Nov 11;36(5):559-573.e7. doi: 10.1016/j.ccell.2019.09.007. Epub 2019 Oct 24. Cancer Cell. 2019. PMID: 31668946 Free PMC article.
Correction to: Optimizing 90Y Particle Density Improves Outcomes After Radioembolization.
Maxwell AWP, Mendoza HG, Sellitti MJ, Camacho JC, Deipolyi AR, Ziv E, Sofocleous CT, Yarmohammadi H, Maybody M, Humm JL, Schwartz J, Juluru K, Dunphy MP, Boas FE. Maxwell AWP, et al. Among authors: dunphy mp. Cardiovasc Intervent Radiol. 2022 Jul;45(7):1055. doi: 10.1007/s00270-022-03171-6. Cardiovasc Intervent Radiol. 2022. PMID: 35641607 No abstract available.
36 results